MiNK Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2017-01-01
- Employees
- 31
- Market Cap
- $32.4M
- Introduction
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- MiNK Therapeutics
- Target Recruit Count
- 34
- Registration Number
- NCT05108623
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Norton Cancer Health, Louisville, Kentucky, United States
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- MiNK Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT04754100
- Locations
- 🇺🇸
Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida, Louisville, Kentucky, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- MiNK Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04582201
- Locations
- 🇺🇸
Saint John's Cancer Institute, Santa Monica, California, United States
🇺🇸Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
🇺🇸Weill Cornell Medicine New York Presbyterian, New York, New York, United States